In melanoma, TAM-derived TNFα mediated resistance to MAPK pathway inhibitors, and applying TNFα signaling inhibitor targeted the cancer cells and TME sensitizing the tumor to immunotherapy (Smith et al., 2014). The gene discussed is TNF; the disease is neoplasm.